VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/41915393/

⇱ Personalized Decision-Making in Risk-Reducing Surgery of the Ovaries - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Importance: Premenopausal women at familial or hereditary risk of ovarian cancer must weigh the risks and benefits of risk-reducing surgery. How they navigate this decision is not well understood.

Objective: To assess the factors that motivate women to seek risk-reducing surgery for ovarian cancer.

Design, setting, and participants: A discrete choice experiment enrolled premenopausal women seeking genetic testing for ovarian cancer risk at 2 tertiary-level cancer centers between August 2019 and January 2022. The experiment was conducted twice, once just prior to pretest counseling and again approximately 2 months later, after receiving results of genetic testing. Data analysis was conducted between June 2022 through January 2026.

Main outcomes and measures: Conjoint analysis to assess factors influencing cancer-prevention decisions in women with risk of familial and hereditary ovarian cancer. Conjoint analysis was used to investigate which attributes were the most salient for women when considering treatment scenarios, with demographic and clinical data as modifiers. Participants were asked to choose between sets of randomly permuted scenarios specifying type of treatment, risk and age of ovarian cancer, risk of heart disease and osteoporosis, and features of menopause.

Results: The participants included 355 women (median age, 37 years [range, 21-55 years]): 10.4% were Black, 7.6% were Hispanic, 85.1% were White, and 79.2% were college graduates. Family history of breast cancer was reported by 45.1%, ovarian cancer by 13.0%, and 11.3% had a personal history of breast cancer. Women preferred risk-reducing salpingo-oophorectomy (RRSO) to risk-reducing salpingectomy (RRS) or observation (odds ratio [OR], 1.24; 95% CI, 1.10-1.39). Differences in osteoporosis (OR, 0.83; 95% CI, 0.78-0.89) and heart disease (OR, 0.78; 95% CI, 0.73-0.84) risks affected choices. Preferences favored natural menopause (OR, 1.21; 95% CI, 1.11-1.33) and milder menopausal symptoms (OR, 0.66; 95% CI, 0.61-0.70). Family history of ovarian cancer increased preference for RRSO (OR, 1.26; 95% CI, 1.05-1.52), with a reduced effect in older women. Personal breast cancer history, ancestry, and genetic test results were not significant factors.

Conclusions and relevance: This survey study using conjoint analysis highlights the ability of women to weigh competing risks in reducing ovarian cancer. Counseling models that address decision complexity and incorporate personalized guidance are likely to improve the decision-making process.

PubMed Disclaimer

Conflict of interest statement

Dr Daly reported grants from the National Cancer Institute (NCI) outside the submitted work. Dr Egleston reported grants from the US National Institutes of Health (NIH)/NCI (P30CA006927, R01 CA207365) as salary support paid to their institution during the conduct of the study. Mr Husband reported grants from the NCI/NIH/Department of Health and Human Services during the conduct of the study. Ms Stopfer reported honoraria for educational presentations from Ambry Genetics and Phenotips. Ms Tchuvatkina reported grants from NCI during the conduct of the study and grants from NCI outside the submitted work. No other disclosures were reported.

Figures

👁 Figure.
Figure.. Flow Diagram of the Study Schema
DFCI indicates Dana-Farber Cancer Institute; FCCC, Fox Chase Cancer Center.

References

    1. Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. J Natl Cancer Inst Cancer Spectr. 2020;4(4):pkaa029. doi: 10.1093/jncics/pkaa029 - DOI - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. ; BRCA1 and BRCA2 Cohort Consortium . Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-2416. doi: 10.1001/jama.2017.7112 - DOI - PubMed
    1. Petrova D, Cruz M, Sánchez MJ. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: a scoping review and a primer on ethical implications. Breast. 2022;61:66-76. doi: 10.1016/j.breast.2021.12.005 - DOI - PMC - PubMed
    1. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703-4709. doi: 10.1093/hmg/ddu172 - DOI - PMC - PubMed
    1. Witjes VM, van Bommel MHD, Ligtenberg MJL, et al. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecol Oncol. 2022;164(1):221-230. doi: 10.1016/j.ygyno.2021.10.072 - DOI - PubMed
Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.